BioSpace News Archive

PLx Pharma Inc., a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, VAZALORE™ 325 mg and VAZALORE™ 81 mg, announced that the U.S. Food and Drug Administration is providing clarification for the regulatory path forward for VAZALORE.

Osmotica Pharmaceuticals plc, a fully integrated biopharmaceutical company, announced the commencement of a proposed public offering of 6,000,000 ordinary shares.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted two newly-hired employees options to purchase an aggregate of 20,000 shares of BioCryst common stock on December 31, 2019 as inducements material to each employee entering into employment with BioCryst.

Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that the company is scheduled to present at the 38th Annual J.P. Morgan Healthcare Conference

FibroGen, Inc. announced that its Board of Directors unanimously appointed Enrique Conterno as the company’s Chief Executive Officer and a member of the Board of Directors.

Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that the Company will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 16, 2020 at 11:30 a.m. PT.

Parallax Health Sciences, Inc., an outcome-driven connected healthcare company, announced its intent at asserting and monetizing its intellectual property patent rights within the Human Diagnostics and Behavioral Healthcare markets.

Sorrento Therapeutics announced that its partner Mabpharm filed recently a New Drug Application for the Infliximab biosimilar antibody in China.

Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that it refinanced its debt facility by entering into a new $45 million term loan agreement with its current lenders, investment affiliates managed by Solar Capital Partners, LLC, on December 31, 2019.

Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of central nervous system (CNS) disorders, today announced the completion of patient screening in its ongoing Phase 3 trial with roluperidone to treat negative symptoms in schizophrenia.